OPOlga Ponomarova

Olga Ponomarova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Olga Ponomarova has a total of 40 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Breast cancer in Ukraine: clinics and diagnostics. Current status and prospects of diagnostics (lecture)

    by A. Samusieva, V. Zaichuk, O. Shcherbina, P. Gordiichuk, О.в. Пономарьова, B. Sorokin, П.о. Король, M. Gordiichuk, П.і. Гордійчук, Б.в. Сорокін, et al.

    The lecture discusses the current state of early Breast Cancer (BC) diagnosis in Ukraine, outlining its epidemiological features, morphological heterogeneity, clinical manifestations, and modern diagnostic methods. BC remains the most common oncological disease among women worldwide, including Ukraine. Each year, over 12,000 new cases are registered in the country, with many patients seeking medical help at advanced stages, which decreases treatment effectiveness and survival rates. The lecture stresses the importance of early diagnosis, achievable through increased physician awareness and widespread screening programs. It summarizes current knowledge on the clinicopathological subtypes of BC, assessment of hormonal receptor status, and the role of immunohistochemical and molecular-genetic testing in treatment decisions. Diagnostic imaging techniques (mammography, tomosynthesis, ultrasound, magnetic resonance imaging) and their diagnostic value are discussed, along with clinical examination algorithms. Special emphasis is placed on modern technologies, especially artificial intelligence, in automated image analysis for mammography and ultrasound. The integration of deep learning with medical imaging data improves diagnostic accuracy, allows detection of pathological changes at the preclinical stage, and reduces diagnostic errors. A key focus is the multidisciplinary approach to managing BC patients, which involves coordination among healthcare providers, adherence to current clinical protocols, and the use of genomic assays (such as Oncotype DX, MammaPrint), with personalized treatment plans. The lecture underlines the necessity of ongoing professional development for healthcare workers at all levels through postgraduate education, aiming to establish standardized algorithms for early BC detection. Overall, the lecture aims to provide students with a thorough understanding of modern principles in breast cancer diagnostics and strategies for enhancing their effectiveness in Ukraine, considering global trends, national challenges, and innovative approaches. Keywords: breast cancer symptoms, diagnostic algorithm, artificial intelligence in diagnosis.

  • Open Access

    Exploring New Frontiers: Alternative Breast Cancer Treatments Through Glycocalyx Research

    by Ielizaveta Gorodetska, Anastasiia Samusieva, Tetiana Lahuta, Olga Ponomarova, Oleg Socha, Iryna Kozeretska

    Breast cancer (BC) treatment is developing toward more precise and personalized care through the approval of different comprehensive approaches. Clinical practice emphasizes significant patient‐to‐patient variability in treatment response among patients, even those with similar clinical and biological profiles. Recent studies have demonstrated that the glycocalyx is an essential organelle that plays an important role in many cellular processes and can be a promising target for treatment. The glycocalyx of cancer cells is a key component influencing the interaction between the tumor and the immune system. Glycan modifications attached to glycoproteins and glycolipids are a common characteristic of the transition to malignancy. We review how the specific structure and function of the glycocalyx are regulated at the molecular level, contribute to immune evasion, and can be overcome by using both traditional drugs and combination therapies, as well as drugs not previously used in standard cancer treatments, to address treatment resistance associated with glycocalyx alterations. Trial Registration: ClinicalTrials.gov identifier: NCT00770354, NCT00925548, NCT01731587, NCT00088413, NCT00179309, NCT00986609, NCT05812326, NCT04020575, NCT05239143, NCT01279603, and NCT03562637


  • Contribution of BRCA1 5382insC mutation to triplene-gative and luminal types of breast cancer in Ukraine

    by Anastasiia Samusieva, Svitlana Serga, Sergiy Klymenko, Lyudmila Rybchenko, Bohdana Klimuk, Liubov Zakhartseva, Natalia Gorovenko, Olga Lobanova, Zoia Rossokha, Liliia Fishchuk, et al.

    Purpose The gene BRCA1 plays a key role in DNA repair in breast and ovarian cell lines and this is considered one of target tumor suppressor genes in same line of cancers. The 5382insC mutation is among the most frequently detected in patients (Eastern Europe) with triple-negative breast cancer (TNBC). In Ukraine, there is not enough awareness of necessity to test patients with TNBC for BRCA1 mutations. That is why this group of patients is not well-studied, even through is known the mutation may affect the course of disease. Methods The biological samples of 408 female patients were analyzed of the 5382insC mutation in BRCA1. We compared the frequency of the 5382insC mutation in BRCA1 gene observed in Ukraine with known frequencies in other countries. Results For patients with TNBC, BRCA1 mutations frequency was 11.3%, while in patients with luminal types of breast cancers, the frequency was 2.8%. Prevalence of 5382insC among TNBC patients reported in this study was not different from those in Tunisia, Poland, Russia, and Bulgaria, but was higher than in Australia and Germany. Conclusion The BRCA1 c.5382 mutation rate was recorded for the first time for TNBC patients in a Ukrainian population. The results presented in this study underscore the importance of this genetic testing of mutations in patients with TNBC. Our study supports BRCA1/2 genetic testing for all women diagnosed with TNBC, regardless of the age of onset or family history of cancer and not only for women diagnosed with TNBC at <60y.o., as guidelines recommend.


  • An association of XRCC1 codon 399 polymorphism (RS25487) with bladder and prostate cancer susceptibility in the Ukrainian population

    by Yaroslava Mishchuk-Reka, Yevhenia Kharkivska, Svitlana Serga, Eduard Stakhovskyi, Oleksandr Stakhovskyi, Oleksii Kononenko, Oleksandr Koliada, Olga Ponomarova, Roman Gulkovskyi, Liudmyla Ostapchenko, et al.